Infliximab for the treatment of psoriasis

    Research output: Contribution to journalArticlepeer-review


    Psoriasis is a common immune-mediated skin disease producing significant morbidity. Tumour necrosis factor (TNF)-α, a pro-inflammatory cytokine, plays a key role in the cutaneous inflammation characteristic of psoriasis. Infliximab is a chimeric monoclonal antibody that specifically binds to TNF-α, thereby blocking its biological activity. Data from Phase II and III studies indicate that infliximab is a highly effective, rapidly acting systemic therapy for patients with moderate-to-severe psoriasis. Regular 8-weekly infusions of infliximab maintain significant clinical improvement in the majority of patients for at least 1 year. Infliximab is generally well tolerated, but patients may be susceptible to infection and malignancy. © 2006 Informa UK Ltd.
    Original languageEnglish
    Pages (from-to)797-805
    Number of pages8
    JournalExpert opinion on biological therapy
    Issue number8
    Publication statusPublished - Aug 2006


    • Biologicals
    • Infliximab
    • Psoriasis
    • Randomised controlled trials
    • TNF-α


    Dive into the research topics of 'Infliximab for the treatment of psoriasis'. Together they form a unique fingerprint.

    Cite this